Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder

By Josep Antoni Ramos-Quiroga   Bosch Rosa   Castells Xavier   Valero Sergi   Nogueira Mariana   Gómez Nuria   Yelmo Silvia   Ferrer Marc   Martínez Yolanda   Casas Miguel  

CNS Drugs, Vol. 22, Iss. 7, 2008-01 ,pp. : 603-611

Adis International

Access to resources Recommend Favorite

OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder

By McBurnett Keith   Starr H Lynn  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 315-324

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Methylphenidate Controlled-Delivery Capsules (Equasym™XL, Metadate CD™) in the Treatment of Children and Adolescents with Attention-Deficit Hyperactivity Disorder

By Anderson Vanessa R.   Keating Gillian M.  

CNS Drugs, Vol. 21, Iss. 2, 2007-01 ,pp. : 173-175

Adis International

Access to resources Recommend Favorite

Methylphenidate Transdermal System: In Attention-Deficit Hyperactivity Disorder in Adolescents

By Keating Gillian M.  

CNS Drugs, Vol. 25, Iss. 4, 2011-04 ,pp. : 333-342

Adis International

Access to resources Recommend Favorite

Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder

By Stiefel Gary  

Drug Safety, Vol. 33, Iss. 10, 2010-10 ,pp. : 821-842

Adis International

Access to resources Recommend Favorite